Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy. | NCT07736911

NCT07736911

Overview

NCT ID: NCT07736911
Lead Sponsor: Fu Jen Catholic University HospitalOTHER
Official Title: Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy: A Randomized Controlled Trial.
Brief Summary: This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week drug interruption constitutes an appropriate pre-procedural recommendation.
Conditions: GLP-1
Interventions

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

• Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week).

Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose.

Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication.

Age between 18 and 70 years.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Provision of written informed consent.

Outpatient status.

If currently receiving medications that stimulate or inhibit gastrointestinal motility, these agents must be discontinued at least 3 days prior to EGD.

Exclusion Criteria:

• Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis).

History of prior upper gastrointestinal resection (stomach, intestine, or esophagus).

Any other condition deemed inappropriate by the treating physician.

Body mass index (BMI) > 40 kg/m².

Liver cirrhosis.

Parkinson's disease.

Dementia.

Use of tricyclic antidepressants or opioid medications for more than 3 months.